Phenotypic Approaches to Identify Inhibitors of B Cell Activation

por Rex, Elizabeth B., Kim, Suzie, Wiener, Jake, Rao, Navin L., Milla, Marcos E., DiSepio, Daniel
Publicado 2015

Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo

por Wong, Eitan, Cohen, Tal, Romi, Erez, Levin, Maxim, Peleg, Yoav, Arad, Uri, Yaron, Avraham, Milla, Marcos E., Sagi, Irit
Publicado 2016

Isoproterenol Acts as a Biased Agonist of the Alpha-1A-Adrenoceptor that Selectively Activates the MAPK/ERK Pathway

por Copik, Alicja. J., Baldys, Aleksander, Nguyen, Khanh, Sahdeo, Sunil, Ho, Hoangdung, Kosaka, Alan, Dietrich, Paul J., Fitch, Bill, Raymond, John R., Ford, Anthony P. D. W., Button, Donald, Milla, Marcos E.
Publicado 2015

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer

por Eisner, Joel R., Beebe, Kirk D., Mayhew, Gregory M., Shibata, Yoichiro, Guo, Yuelong, Farhangfar, Carol, Farhangfar, Farhang, Uronis, Joshua M., Mooney, Jill, Milburn, Michael V., Foureau, David, White, Richard L., Amin, Asim, Milla, Marcos E.
Publicado 2022

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

por Ptacin, Jerod L., Caffaro, Carolina E., Ma, Lina, San Jose Gall, Kristine M., Aerni, Hans R., Acuff, Nicole V., Herman, Rob W., Pavlova, Yelena, Pena, Michael J., Chen, David B., Koriazova, Lilia K., Shawver, Laura K., Joseph, Ingrid B., Milla, Marcos E.
Publicado 2021